KV Pharmaceutical Company Appoints Two New Board Members

           KV Pharmaceutical Company Appoints Two New Board Members

PR Newswire

ST. LOUIS, Oct. 11, 2013

ST. LOUIS, Oct. 11, 2013 /PRNewswire-USNewswire/ -- K-V Pharmaceutical Company
("KV") today announced the appointment of two new members to its Board of
Directors: Gregory Norden, former Senior Vice President and Chief Financial
Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of
Infertility Services of the University Hospitals of Cleveland Health Systems
and Clinical Professor of Reproductive Biology at Case Western Reserve
University (CWRU) School of Medicine.

"Greg Norden and Dr. Goldfarb's breadth of knowledge and experience will
provide invaluable insight to KV as we continue to grow the business and
strive to deliver innovative women's healthcare products," said Greg Divis,
CEO of KV.

Norden and Dr. Goldfarb will join former President of Wyeth Pharmaceuticals,
Joseph M. Mahady, as the newest members of KV's board. KV announced Mahady's
appointment as Chairman of the Board on Oct. 3, 2013.

"I'm pleased to welcome Greg and Jim to the board. Greg brings an
extraordinary depth of financial experience developed across his operating and
board roles, while Dr. Goldfarb brings critical perspective as a scientist,
physician and patient advocate," said Mahady.

Norden brings to KV more than 25 years of leadership experience in financial
management and more than 20 years of experience in global healthcare and
pharmaceuticals. He is currently the managing director of G9 Capital Group,
LLC, which invests in early stage ventures and provides corporate finance
advisory services. Norden sits on the boards of Zoetis, a global leader in
discovering, developing, manufacturing and commercializing animal health
medicines and vaccines, NanoString Technologies, a provider of life science
tools for translational research and development of molecular diagnostic
products, and Welch Allyn, a global provider of medical diagnostic equipment.
Before joining Wyeth, Norden was with Arthur Andersen and Co., working
primarily with multi-national companies in the consumer goods and financial
services industries.

Dr. Goldfarb is known as a pioneer in the field of infertility and is past
president of the Society for Assisted Reproductive Technologies (SART), a
national professional group that provides leadership to the country's In Vitro
Fertilization (IVF) programs. Dr. Goldfarb co-founded the Partnership for
Families Program, which provides free IVF cycles for qualifying couples, among
other services. His infertility programs have been credited for many firsts,
including the first IVF birth in Ohio in 1983 and the world's first
IVF/surrogate birth in 1986.In addition, he co-founded Rapid Medical Research
(RMR), which is a multi-therapeutic clinical research center offering a wide
range of services and support to pharmaceutical and biotechnology companies.
Dr. Goldfarb sold RMR in 2006. He has been a consultant to private equity
firms on various healthcare related investments and has held a number of board
positions, including with the Miami University Business School Advisory Board
and the American Society of Reproductive Medicine Board of Directors. Dr.
Goldfarb earned his medical degree from the Ohio State University School of
Medicine and his master of business administration from the Case Western
Reserve University Weatherhead School of Management.

About KV Pharmaceutical
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with
a primary focus in the area of women's healthcare. The company is committed to
advancing the health of women across the stages of their lives.For further
information about K-V Pharmaceutical Company, please visit www.kvph.com.

SOURCE K-V Pharmaceutical Company

Website: http://www.kvph.com
Press spacebar to pause and continue. Press esc to stop.